I'm not very surprised it was pulled. Don came scross as too confident for my liking, making statements that could not be justified. He didn't sound like a CEO of a biotech company, more like a salesman. Such a pity that a drug with such great prospects is in his hands. But I have just read the recent papers in Cell and Biomedicine again, and older papers showing reduced IL-1beta effect (driver of cytokine storms). The data are very impressive. That's what really matters. So plenty to be positive about. I can't imagine a drug with better credentials for a covid trial.